Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of SHR-A1811 combination therapy in HER2-positive advanced or metastatic biliary tract cancer
CTR20250105Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in biliary cancer, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Mar 2025; status: active.
02
Drugs
trastuzumab rezetecan
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20250105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250105.